Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

5.6%

2 terminated out of 36 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

8%

3 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed with results

Key Signals

3 with results83% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (6)
Early P 1 (3)
P 1 (6)
P 2 (11)
P 3 (3)

Trial Status

Recruiting17
Completed10
Terminated2
Active Not Recruiting2
Unknown2
Suspended1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT07441707Phase 1RecruitingPrimary

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

NCT07110246Phase 2Recruiting

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT05555550Early Phase 1Recruiting

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT03363217Phase 2Active Not RecruitingPrimary

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

NCT04485559Phase 1Suspended

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT07506239Not ApplicableRecruitingPrimary

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

NCT05566795Phase 3RecruitingPrimary

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT06104488Phase 1Recruiting

A Study of Avutometinib for People With Solid Tumor Cancers

NCT03429803Phase 1CompletedPrimary

DAY101 In Gliomas and Other Tumors

NCT05406700Early Phase 1Active Not RecruitingPrimary

Niraparib In Recurrent IDH 1/2 Gliomas

NCT04923126Phase 1RecruitingPrimary

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

NCT04865315RecruitingPrimary

A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

NCT03948490Not ApplicableRecruitingPrimary

Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas

NCT06930846Not ApplicableRecruiting

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

NCT04734444Not ApplicableCompleted

SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue

NCT07004075Phase 3Not Yet RecruitingPrimary

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

NCT06381570Early Phase 1RecruitingPrimary

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

NCT04775485Phase 2RecruitingPrimary

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04544007Phase 2Terminated

A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

NCT06684795Phase 2RecruitingPrimary

FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery

Scroll to load more

Research Network

Activity Timeline